BCR and chronic myelogenous leukemia, BCR-ABL1 positive: It has also been shown that FANCD2 downregulation and FANCD2-Ub inhibition lowered CD34+ CML cells’ clonogenic capacity and delayed BCR-ABL1 leukemogenesis in CML mouse models [36].